JANX011 Phase 1 Healthy Volunteer Data and Autoimmune Development Strategy - JANUX THERAPEUTICS INC

Financial Performance:

• No specific revenue, earnings, or cash flow figures disclosed for Q4 2024; company remains in clinical development stage with no commercial products.
• Capital position estimated at approximately $950 million following recent filings, deemed sufficient to fund the full clinical assessment of the oncology franchise (prostate cancer) and the new autoimmune strategy.
• No debt information provided; focus remains on capital allocation for advancing Janix 011 and other platform assets.

Guidance and Future Outlook:

• Intends to initiate autoimmune patient studies for Janix 011 in ITP and Rheumatoid Arthritis (RA) within the next 12 months, potentially starting at 1mg or 3mg doses pending regulatory feedback.
• Plans to optimize the dosing regimen in patients using step-up and repeat dosing strategies to potentially deepen B-cell depletion and further reduce Grade 1 CRS incidence.
• Strategic goal is to translate healthy volunteer validation into patient proof-of-concept to expand the ARM platform to other autoimmune targets and potential HEMO/oncology indications.
• Will evaluate capital formation or partnership opportunities only after generating value-creating patient data in autoimmune disease, rather than pre-data.

Business Segments and Product Lines:

• ARM Platform (Autoimmune): First-in-human validation achieved with Janix 011; a CD19-targeted bispecific antibody designed to selectively recruit TRBV6+ T-cells (approx. 10% of T-cells) for deep B-cell depletion.
• Janix 011: Completed Phase 1 Healthy Volunteer study with 3,000 mcg subcutaneous dosing; achieved >90% B-cell depletion in most subjects, undetectable levels in two, and Grade 1 only CRS without step-up dosing.
• Oncology Portfolio: Maintains focus on Tractor and Tracer platforms (CD3/CD28 targets); continues progression of Janix 007, 013, and 014 with no change to prostate cancer commitment.
• Manufacturing: Process demonstrated at 500L scale with formulation flexibility for both IV and subcutaneous administration, optimized for outpatient delivery.

Market and Competitive Landscape:

• Positions Janix 011 against a gap between CAR-T (deep depletion but high toxicity/complexity) and conventional antibodies (convenient but shallow depletion).
• Differentiates from conventional T-cell engagers (e.g., Teclistamab, Talquetamab) by avoiding broad CD3 engagement, aiming to reduce cytokine release syndrome (CRS) severity and preserve immune function in the non-targeted 90% of T-cells.
• Competes on convenience (single SC dose) and tolerability; current data suggests a more favorable profile than existing CD19 T-cell engagers which often require step-up dosing and report Grade 2-3 CRS.

Risks and Challenges:

• Safety: Transient, asymptomatic ALT/AST elevations observed in the highest dose cohort; managed with standard monitoring and anticipated to be modulated via step-up dosing and steroid use in patients.
• Efficacy Durability: Unknown duration of B-cell depletion in patients; early healthy volunteer data shows depletion persisting through Day 42, but long-term durability requires patient trials and potential repeat dosing.
• Target Availability: While TRBV6 expression is consistent (8-12%) across healthy and autoimmune patients, theoretical risks regarding tissue trafficking and barrier function persistence remain to be validated.
• Development Execution: Need to successfully optimize dose/regimen in patients to ensure translation of the favorable healthy volunteer profile into clinical benefit.

Management Commentary and Tone:

• Tone is highly confident and data-driven, framing the healthy volunteer results as a "differentiated starting position" rather than a final clinical regimen.
• Management emphasizes the "design thesis" validation: selective T-cell recruitment can achieve deep biology with controlled toxicity.
• CEO Dr. David Campbell expressed satisfaction with the "first human validation" of the ARM platform, viewing the healthy volunteer data as proof of concept rather than a ceiling.
• Management maintains a disciplined approach, stating they will not lock in a regimen but will let patient data guide optimization.

Analyst Questions and Answers:

• T-Cell Trafficking: Management cited preclinical and public data suggesting TRBV6+ naive/memory T-cells reside in lymph nodes, supporting efficacy in tissue compartments despite peripheral data.
• CRS Prophylaxis: Confirmed Dexamethasone (DEX) was used prophylactically for all patients, but no therapeutic DEX or Tocilizumab was used to treat CRS events; all Grade 1 CRS were managed with acetaminophen alone.
• Liver Toxicity: One Grade 3 ALT elevation in the 3,000 mcg cohort; described as transient, asymptomatic, and typical of T-cell engagers, expected to be mitigated in patients using step-up dosing.
• Dosing Strategy: Anticipate starting patient trials at 1mg or 3mg; expect to explore step-up, repeat, and higher doses to improve tolerability and durability.
• Variability: Variability in the 3,000 mcg cohort attributed to one patient with suboptimal PK exposure; response rates were consistent (89%+) in other subjects.
• Infection Risk: Management argues that preserving 90% of the T-cell repertoire (excluding TRBV6) maintains barrier function and viral/fungal defense, contrasting with broad CD3 engagers.
• Self-Administration: Subcutaneous formulation and Grade 1 CRS profile suggest potential for outpatient/self-administration, pending final patient tolerability data.

Other Key Points:

• Platform Potential: ARM is positioned as a long-term growth platform, not just a single asset; learnings from Janix 011 will inform future programs targeting other disease-driving cells.
• Selection of ITP/RA: ITP selected for its rapid, quantitative readout (platelets); RA selected for large patient population and validated CD19 targeting.
• No Pre-screening Required: TRBV6 levels are consistent (8-12%) across populations, eliminating the need for patient pre-screening/testing.
• Future Updates: Communication strategy for Janix 011 remains flexible; may provide updates more frequently than the "fully baked" cadence used for oncology assets if patient enrollment allows.